New hope for rare anemias: drug may cut transfusions
NCT ID NCT07331818
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This Phase 2 trial tests the drug luspatercept (Reblozyl) in 45 people with rare inherited anemias that affect red blood cells. The goal is to see if it can reduce the need for blood transfusions in those who depend on them, or raise hemoglobin levels in those who don't. Participants will receive injections over several weeks, and researchers will monitor their response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Luspatercept (Reblozyl)
What this could lead to
If successful, this could offer a new treatment option to reduce blood transfusions or increase hemoglobin levels for people with rare inherited anemias.
What could go wrong
This is an early Phase 2 trial with only 45 participants, so results may not apply to all patients. The drug may not work for every type of anemia, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIAMOND-BLACKFAN ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Assistance Publique Hôpitaux de Paris - Hôpital Necker
Paris, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Assistance Publique Hôpitaux de Paris - Hôpital Saint-Louis
Paris, 75010, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU Bordeaux-Hôpital Haut-Lévêque
Pessac, 33600, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Centre Hospitalier Universitaire de Montpellier
Montpellier, 34295, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano
Milan, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
GCS Groupement des Hôpitaux de l'Institut Catholique de Lille
Lille, 59800, France
Contact Email: •••••@•••••